2021 年第三季度报告 单位：元 币种：人民币 证券代码：603127 证券简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|---------------------------|----------------|------------------------- ...

2021 年半年度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2021 年半年度报告 1 / 163 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人冯宇霞、主管会计工作负责人于爱水及会计机构负责人（会计主管人员）于爱水 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告涉及未来计划、发展战略等前瞻性描述，因存在不确定性因素，不构成公司对 投资者的实质性承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司在本半年度报告中已 ...

Financial Performance - Net profit attributable to shareholders was RMB 93.36 million, up 388.07% year-on-year[4] - Operating revenue for the period was RMB 200.99 million, representing a growth of 29.91% compared to the same period last year[4] - Basic earnings per share rose to RMB 0.39, a 333.33% increase from RMB 0.09 in the previous year[4] - Excluding the impact of foreign exchange gains, net profit growth rate was 85.44%[4] - The company reported a total comprehensive income of ¥62,388,926.44 for Q1 2021, compared to ¥22,630,107.43 in Q1 2020[23] - The company's net profit for Q1 2021 was CNY 56,060,823.09, a significant increase compared to CNY 934,455.09 in Q1 2020, reflecting a growth of approximately 5,900%[25] - Total revenue from operating activities reached CNY 334,525,902.11, up from CNY 232,670,305.50 in the same period last year, indicating a growth of about 43.8%[27] Assets and Liabilities - Total assets reached RMB 7.63 billion, an increase of 262.17% compared to the end of the previous year[4] - Total liabilities increased to ¥1,037,666,885.26, up from ¥883,657,479.78, representing a growth of approximately 17.5% year-over-year[16] - Current liabilities totaled ¥875,120,280.13, compared to ¥760,042,162.51, indicating an increase of about 15.1%[16] - Non-current liabilities rose to ¥162,546,605.13 from ¥123,615,317.27, reflecting a growth of approximately 31.5%[16] - Total equity attributable to shareholders reached ¥6,597,313,422.62, significantly up from ¥1,224,899,092.29, marking an increase of around 438.5%[17] - Total assets of the company reached ¥7,633,988,121.93, a substantial increase from ¥2,107,821,636.06, reflecting overall growth in the company's financial position[15] - Total liabilities amounted to ¥883,657,479.78, a decrease of ¥67,435,620.28 compared to the previous period[33] Cash Flow - The company reported a net cash flow from operating activities of RMB 34.48 million, a slight increase of 0.49% year-on-year[4] - Cash and cash equivalents increased significantly to ¥5,657,723,895.31 from ¥308,689,959.55, a change of 1732.82% due to funds raised from the Hong Kong stock market[9] - The net cash flow from financing activities was ¥5,312,443,354.88, a dramatic increase of 331480.4% compared to ¥1,602,158.28 in the previous period, mainly due to funds raised from the Hong Kong stock market[12] - Cash inflow from operating activities totaled CNY 127,310,706.37, a significant increase of 86% compared to CNY 68,375,500.49 in Q1 2020[30] - The net increase in cash and cash equivalents was CNY 5,365,357,040.52, compared to a decrease of CNY 6,288,742.53 in the previous year[31] Shareholder Information - The number of shareholders reached 21,198 by the end of the reporting period[7] - The top shareholder, Feng Yuxia, holds 23.66% of the shares, totaling 64,073,468 shares[8] Other Financial Metrics - The weighted average return on equity increased by 0.80 percentage points to 3.08%[4] - The company completed its H-share listing on February 26, 2021, raising HKD 6.373 billion, with a foreign exchange gain impacting net profit by RMB 57.89 million[4] - The company incurred financial expenses of CNY 67,971,575.70, compared to CNY 45,241.27 in the previous year, indicating a rise in financial costs[25] - Research and development expenses for Q1 2021 were ¥9,878,808.23, a decrease of 16% from ¥11,760,553.48 in Q1 2020[22]

Financial Performance - In 2020, the company's operating revenue reached approximately CNY 1.08 billion, representing a year-on-year increase of 68.27%[17]. - The net profit attributable to shareholders was approximately CNY 291.92 million, an increase of 78.91% compared to the previous year[17]. - The basic earnings per share for 2020 was CNY 1.40, up 68.67% from CNY 0.83 in 2019[18]. - The total assets of the company at the end of 2020 were approximately CNY 2.11 billion, a 45.97% increase from the previous year[17]. - The company reported a net cash flow from operating activities of approximately CNY 428.39 million, a significant increase of 189.27% year-on-year[17]. - The weighted average return on equity for 2020 was 30.78%, an increase of 5.28 percentage points compared to 2019[18]. - The company achieved a quarterly revenue of CNY 444.39 million in Q4 2020, contributing to a total annual revenue of CNY 1.08 billion[21]. - The company reported a significant increase in clinical services revenue, which grew by 327.49% year-on-year[59]. - The company reported a total comprehensive income of 342,139,007.58 CNY, up from 185,892,576.85 CNY, which is an increase of approximately 84.0%[196]. Shareholder Information - The company plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares, and to increase capital by converting 4 shares for every 10 shares held[4]. - The total number of ordinary shares increased from 161,716,920 to 227,454,729 after the implementation of the 2019 annual equity distribution plan[134]. - The top shareholder, Feng Yuxia, holds 64,073,468 shares, representing 28.17% of the total shares[143]. - The second-largest shareholder, Zhou Zhiwen, has 34,568,986 shares, accounting for 15.20%[143]. - The third-largest shareholder, Gu Xiaolei, owns 16,078,455 shares, which is 7.07% of the total[143]. - The total number of shares held by the top ten shareholders is significant, with the largest four shareholders alone holding over 50% of the total shares[143]. - The report indicates that there are no known relationships or concerted actions among the top shareholders, except for familial ties between some[144]. Corporate Governance - The company has received a standard unqualified audit report from KPMG Huazhen[3]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy[3]. - The company has established a rigorous governance structure to protect the rights of all shareholders, including minority shareholders[171]. - The company maintains independence from its controlling shareholders, ensuring no interference in decision-making or operations[171]. - The company has not reported any major differences in governance practices compared to the requirements set by the China Securities Regulatory Commission[172]. - The company has a board of directors consisting of ten members, including four independent directors, and has established four specialized committees[171]. Market and Industry Outlook - The domestic CRO market is expected to grow due to rising investment in drug development and the increasing internationalization of domestic CRO capabilities[34]. - The global CRO market size was approximately $62.6 billion in 2019 and is expected to reach $96 billion by 2024, with a CAGR of about 8.9% from 2019 to 2024[38]. - The Chinese CRO market size was around $6.8 billion in 2019, projected to grow to $22.2 billion by 2024, reflecting a CAGR of 26.5%[38]. - The company aims to expand its market share in preclinical pharmacology and toxicology evaluation services, while also enhancing clinical CRO and drug safety services[81]. - The company plans to enhance its international service capabilities and is currently transitioning to the third phase of its internationalization strategy, focusing on international client submissions[84]. Research and Development - The company is investing 10% of its revenue into R&D for new technologies and drug evaluation methods[153]. - The company has expanded its professional service team to nearly 1,500 members by December 31, 2020, improving technical capabilities in preclinical research services[45]. - The company aims to enhance its pharmacology and toxicology research capabilities in 2021, ensuring compliance with regulatory requirements[90]. - The company focuses on drug preclinical research services, which include non-clinical safety evaluation and pharmacodynamics research, essential for drug development[26]. Compliance and Risk Management - The company emphasizes the uncertainty of future plans and development strategies, warning investors of potential risks[5]. - The company faces risks related to regulatory compliance, talent recruitment, and market competition, which could impact its operational performance[92][93][94]. - The company has committed to avoiding competition with its controlling shareholders and related parties, ensuring no direct or indirect business activities that compete with the company[102]. Environmental and Social Responsibility - The company has implemented a comprehensive environmental management system, ensuring 100% compliance in pollutant discharge standards[130]. - The company emphasizes the importance of environmental protection and sustainable development in its operational strategy[129]. - The company has established a waste disposal agreement with a third-party service provider for medical and hazardous waste, with annual disposal amounts of 49.87 tons and 19.344 tons respectively[131]. Employee and Management Information - The total number of employees in the parent company is 423, while the total number of employees in major subsidiaries is 1,060, resulting in a combined total of 1,483 employees[164]. - The company has 1,088 technical personnel, which constitutes the majority of its workforce[165]. - The remuneration policy for management is based on an annual salary system linked to the company's annual performance[166]. - The company conducted a total of 6,557 training sessions in 2020, representing a 7% increase in training participation compared to 2019[167].

2020 年第三季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2020 年第三季度报告 1 / 28 2020 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 28 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人冯宇霞、主管会计工作负责人于爱水及会计机构负责人（会计主管人员）于爱水 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |----------------------------------------------|------------------------------|----------------------------------- ...

2020 年半年度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2020 年半年度报告 1 / 163 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人冯宇霞、主管会计工作负责人于爱水及会计机构负责人（会计主管人员）于爱水 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告涉及未来计划、发展战略等前瞻性描述，因存在不确定性因素，不构成公司对 投资者的实质性承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司在本半年度报告中已描述相关经营风险，详情请查阅本报告第四节经营情况讨论与分析。 十、 其他 □适用 √不适 ...

2020 年第一季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2020 年第一季度报告 1 / 26 2020 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 26 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人冯宇霞、主管会计工作负责人于爱水及会计机构负责人（会计主管人员）于爱水 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-------------------------------------------------|--------- ...

Dividend and Capital Reserve Distribution - The company plans to distribute a cash dividend of 3.4 yuan per 10 shares and issue a capital reserve of 4 shares per 10 shares[4] - In 2019, the company distributed a cash dividend of RMB 54,983,752.8, accounting for 30.82% of the net profit attributable to ordinary shareholders[105] - In 2018, the cash dividend amounted to RMB 34,498,380, representing 31.82% of the net profit attributable to ordinary shareholders[105] - In 2017, the cash dividend was RMB 24,641,700, which was 32.23% of the net profit attributable to ordinary shareholders[105] Corporate Governance and Shareholder Commitments - The company has no non-operational fund occupation by controlling shareholders or related parties[4] - The company has no violations of decision-making procedures for external guarantees[4] - The company's controlling shareholders, Feng Yuxia and Zhou Zhiwen, committed to avoiding同业竞争 and have strictly adhered to this commitment since August 25, 2017[107] - Feng Yuxia and Zhou Zhiwen pledged not to transfer or entrust others to manage their shares for 36 months following the company's listing[107] - 28 other shareholders, including Zuo Conglin and Sun Yunxia, also committed to not transferring or entrusting others to manage their shares for 36 months post-listing[108] - Directors, supervisors, and senior management are restricted from transferring more than 25% of their directly or indirectly held shares annually after the lock-up period[108] - Senior management and directors are required to maintain a减持 price not lower than the IPO price for two years post-lock-up[108] - Feng Yuxia, Zhou Zhiwen, and other key individuals have expressed long-term holding intentions, with减持 limits of 2% and 5% of their holdings in specific periods post-lock-up[108] - The company has committed to stabilizing its stock price by repurchasing shares if the stock price falls below the net asset value per share for 20 consecutive trading days[109] - The company will use its own funds for share repurchases, with the total amount not exceeding the funds raised from the initial public offering[110] - The company's share repurchase plan requires approval from more than half of the board members and two-thirds of the shareholders[110] - The company's single repurchase amount should be between 10% and 20% of the previous year's net profit attributable to the parent company[110] - The company's single repurchase amount should not exceed 2% of the total shares[110] - The total repurchase amount in a fiscal year should not exceed 30% of the previous year's net profit attributable to the parent company[110] - The controlling shareholders will increase their holdings if the stock price remains below the net asset value per share for 10 consecutive trading days after the repurchase plan expires[111] - The controlling shareholders' increase in holdings should not exceed 2% of the total shares within 12 months[112] - The company's directors and senior management will increase their holdings if the stock price remains below the net asset value per share for 10 consecutive trading days after the controlling shareholders' increase in holdings[112] - The company's directors and senior management will use their personal funds to increase their holdings, with the amount not exceeding their total salary from the previous year[113] - The company's controlling shareholders, Feng Yuxia and Zhou Zhiwen, have committed to fulfilling their obligations to stabilize the stock price and will publicly apologize and compensate investors if they fail to do so, unless due to force majeure[116] - The company's directors and senior management have also committed to stabilizing the stock price and will publicly apologize and compensate investors if they fail to fulfill their obligations, unless due to force majeure[117] Subsidiaries and Business Operations - The company's subsidiaries include JOINN Laboratories (Delaware) Corporation and Biomedical Research Models, Inc[7] - The company operates in the contract research organization (CRO) sector, providing preclinical research services[7] - The company holds a 91% stake in Beijing JOINN Mingxun Pharmaceutical Technology Co., Ltd[7] - The company's subsidiaries are located in Beijing, Suzhou, Chongqing, Guangzhou, and Wuzhou[7] - The company is involved in pharmacology, toxicology, and dose-response relationship studies[8] - The company's core business is drug preclinical research services, including non-clinical safety evaluation, pharmacodynamics, animal pharmacokinetics, and drug screening[26] - The company established two GLP laboratories in Beijing and Suzhou for preclinical evaluation, adhering to strict GLP regulations[29] - The company's preclinical research services include safety pharmacology, single-dose toxicity, repeated-dose toxicity, toxicokinetics, reproductive toxicity, genotoxicity, carcinogenicity, local toxicity, and immunogenicity tests[27] - The company's pharmacodynamics research services focus on studying drug mechanisms, dose-response relationships, and PD/PK trials to support clinical trials[28] - The company's subsidiaries, Suzhou Zhaoyan Medicine and Beijing Zhaoyan Medicine, provide early-stage clinical trial services, including regulatory/registration, medical writing, clinical monitoring/auditing, data management, and statistical services[28] - The company's drug safety monitoring services include pharmacovigilance system setup, quality management, case report processing, safety summary report writing, signal and risk management, and safety research[28] - The company's experimental animal supply includes mice, rats, and non-human primates, primarily for internal use and domestic industry demand[29] - The company has established a systematic preclinical drug evaluation technology platform and GLP quality management system, passing GLP certification or inspection in China and multiple countries[30] - The company's core business is providing technical services for drug preclinical evaluation, generating revenue through research service fees[30] - The company expanded its sales team, leading to a significant increase in new clients, strategic partnerships, and order volume[33] - The clinical business focuses on early-stage clinical trials (Phase I and BE trials), offering a one-stop service from preclinical evaluation to clinical trials[33] - The company is developing a leading, efficient, and stable experimental animal genetic resource and gene engineering technology platform, focusing on creating animal disease models for new drug R&D[35] - The company's preclinical research services are driven by increased domestic and international drug R&D investments and the "4+7" volume-based procurement policy, boosting demand for preclinical CRO services[36] - Subsidiary Suzhou Zhaoyan has expanded experimental facilities and increased technical teams to address capacity constraints, gradually releasing production capacity[37] - The company has enhanced its service capabilities, particularly in evaluating innovative drugs, such as ophthalmic drugs and inhalation route administration, strengthening its industry competitiveness[37] - The company's facilities cover approximately 75,000 square meters, with 67,000 square meters in use, including 32,000 square meters for animal housing[50] - The company employs over 1,100 professionals, capable of handling nearly 1,000 experimental projects simultaneously[52] - The company has established an advanced laboratory information management system (LIMS) to enhance data reliability and operational efficiency[52] - The company has accumulated over 20 years of experience in preclinical drug research, conducting nearly 1,200 preclinical studies and evaluation tests from 2017 to 2019[53] - From 2017 to 2019, the company added 598 biologics, 505 chemical drugs, and 35 traditional Chinese medicine drugs to its preclinical research portfolio[53] - The company has conducted over 100 major innovative drug projects supported by national programs and evaluated more than 200 antibody drugs[54] - In the past 3 years, the company completed over 300 international registration projects for drugs entering or about to enter clinical trials abroad[54] - The company passed FDA GLP inspections in 2009 and 2013, becoming one of the first CROs in China to achieve this[55] - The company obtained AAALAC certification in 2008, with subsequent inspections in 2011, 2014, and 2017[55] - The company plans to build a 565-acre primate breeding base in Guangxi with a capacity of 15,000 animals[57] - As of 2019, the company has a professional service team of over 1,100 people[59] - The company implemented a restricted stock and stock option incentive plan in July 2019 to expand employee coverage and motivation[59] - The company completed the renovation of the small animal facility in June 2019, significantly alleviating facility supply constraints. The subsidiary Suzhou Zhaoyan also began using Animal Building 3 and 7 in July 2019, greatly increasing service throughput and capacity. Additionally, a 3,500 square meter functional laboratory, including molecular biology, pathology, biosafety level 2 (P2), and clinical sample analysis labs, was completed and gradually put into use in November 2019[60] - In 2019, the company assisted clients in completing IND applications for over 230 large-molecule innovative drugs, with 60 approvals. The company also established a radioactive isotope laboratory, which, once completed, will enable independent animal PET-CT and other advanced detection technologies[60] - Suzhou Zhaoyan Medicine, established in 2018, has signed contracts with multiple municipal-level hospitals to jointly build early clinical centers. By 2019, two Phase I clinical research centers had completed hardware, team, and quality system construction and began undertaking clinical trial projects[61] - Zhaoyan Mingxun, focusing on drug safety monitoring, has established partnerships with over 50 companies since its inception in 2018, including drug license holders, R&D firms, manufacturers, and CROs. The company also developed a one-stop drug safety management platform, iPVMAP, and a device vigilance platform[62] - The company's subsidiary Suzhou Qichen, established in 2019, has built high-standard cell and molecular biology labs and established a stable large-animal somatic cell experimental system. It is currently working on creating humanized animal models for ophthalmology, oncology, and immunology[63] - As of the end of 2019, the company's backlog of orders was approximately 1.04 billion yuan, a 30% increase year-over-year, providing a solid foundation for future performance growth[64] - In 2019, the company's contract value increased by over 50% compared to 2018, maintaining rapid growth. The company also participated in multiple international academic conferences, significantly enhancing its industry reputation, particularly in ophthalmology drug evaluation[65] - In December 2019, the company completed the acquisition of BIOMERE, a U.S.-based preclinical CRO, marking its first international M&A. This acquisition expands the company's U.S. market presence and enhances its brand influence in overseas markets[66] - The company plans to expand production facilities, aiming to double production capacity within the next 3 years[87] - The company is focusing on building a full-chain service capability, including drug discovery, clinical research, and product sales[88] - The company aims to enhance international service capabilities and establish overseas branch service institutions[88] - The company is developing new technologies and methods to meet the needs of innovative drugs[90] - The company plans to increase investment in international markets and expand its presence in the U.S. and Europe[91] - The company is building a clinical sample bioanalysis laboratory to enhance clinical sample analysis services[92] - The company is creating an international first-class primate research platform through international and domestic cooperation[93] - The company's internationalization strategy for preclinical CRO business is progressing from Phase 2 (domestic clients with international applications) to Phase 3 (international clients with international applications), with the acquisition of Biomere accelerating this transition[95] - Biomere's preclinical business focuses on drug screening and efficacy, and the acquisition enhances the company's integrated service capabilities, facilitating international client expansion[95] - The company plans to expand Biomere's business from the US East Coast to the West Coast, leveraging existing market presence in California[95] - The company aims to increase preclinical business revenue and expand innovative business growth, with a focus on new areas such as antibody targets, nucleic acid vaccines, stem cells, gene therapy, and UCAR[96] - The company plans to expand marketing efforts internationally, increase marketing personnel, and adjust sales incentive policies to drive new business market development[96] - In 2020, the company plans to renovate 5,400 square meters of animal facilities and 4,400 square meters of laboratories in Suzhou to prepare for growing business orders[98] - The company will continue to build new drug evaluation centers in Guangzhou and Chongqing in 2020[98] - The company aims to complete the construction of the Taicang clinical trial base and ensure full operational capability in the second half of 2020[99] - The company plans to expand the clinical CRO team and build capabilities to handle international projects internally without subcontracting[99] - The company will invest in expanding Biomere's facilities, equipment, and personnel to enhance capacity, technical capabilities, and profitability[100] Financial Performance and Metrics - Revenue in 2019 increased by 56.40% year-on-year to RMB 639,379,338.02[17] - Net profit attributable to shareholders of the company in 2019 increased by 64.64% year-on-year to RMB 178,372,735.97[19] - Basic earnings per share in 2019 increased by 65.67% year-on-year to RMB 1.11[20] - Weighted average return on equity in 2019 increased by 6.36 percentage points year-on-year to 24.35%[20] - Total assets at the end of 2019 increased by 24.22% year-on-year to RMB 1,417,837,791.63[19] - Revenue in the fourth quarter of 2019 was RMB 290,924,164.59, the highest among all quarters[22] - Net profit attributable to shareholders of the company in the fourth quarter of 2019 was RMB 101,889,622.52, the highest among all quarters[22] - Government subsidies in 2019 amounted to RMB 10,601,975.01, an increase from RMB 9,199,659.17 in 2018[23] - The company's equity increased by 26.90% year-on-year to RMB 826,518,653.14 at the end of 2019[19] - Cash flow from operating activities in 2019 decreased by 15.89% year-on-year to RMB 148,092,126.18[19] - The company's derivative financial assets had an ending balance of 50,119,315.07 yuan, with a holding period return of 119,315.07 yuan[25] - The company's fund products had an ending balance of 80,581,275.45 yuan, with a holding period return of 581,275.45 yuan[25] - The company's transaction financial assets increased by 100% year-over-year due to increased investment in financial products[48] - Accounts receivable grew by 174.56% year-over-year, driven by increased service provision[48] - Fixed assets increased by 46.05% year-over-year, primarily due to the acquisition of BIOMERE and the transfer of construction in progress to fixed assets[49] - Intangible assets grew by 121.51% year-over-year, mainly due to the acquisition of BIOMERE[49] - Overseas assets amounted to 355,931,801.03 RMB, accounting for 25.10% of total assets[49] - The company's transaction financial assets increased to 1.307 billion yuan, accounting for 9.22% of total assets, primarily due to the reclassification under new accounting standards and increased purchase of financial products with idle funds[79] - Accounts receivable surged by 174.56% to 1.064 billion yuan, driven by increased service provision[79] - Inventory rose by 75% to 2.005 billion yuan, mainly due to increased raw materials and unresolved research projects[79] - Fixed assets grew by 46.05% to 4.183 billion yuan, largely due to the completion of construction projects and the acquisition of BIOMERE[79] - Intangible assets increased by 121.51% to 1.066 billion yuan, primarily due to the acquisition of BIOMERE[79] - Long-term equity investments reached 429.12 million yuan, up from 159.87 million yuan last year, mainly due to the acquisition of BIOMERE for $27.28 million[81][82] - The company invested 64.04 million yuan in the preclinical research base project, with a total investment of 175.79 million yuan by the end of 2019, and the project is expected to be operational by the end of 2020[83] - The experimental animal base project in Wuzhou has a total investment of approximately 400 million yuan, with 11.67 million yuan invested by the end of 2019[83] - Deferred tax assets increased by 257.49% to 260.05 million yuan, mainly due to share-based payments and deductible losses from the BIOMERE acquisition[79] - Deferred tax liabilities surged by 796.33% to 206.44 million yuan, driven by the BIOMERE acquisition and tax benefits on fixed assets[80] - Suzhou Zhaoyan's total assets decreased to 621.46 million yuan in 2019 from 666.17 million yuan in 2018[86] - Suzhou Zhaoyan's net income increased to 134.09 million yuan in 2019 from 81.49 million yuan in 2018[86] - Suzhou Zhaoyan's revenue grew to 394.14 million yuan in 2019 from 250.69 million yuan in 2018[86] - Revenue for the reporting period reached 639.38 million yuan, a year-on-year increase of 56.40%, with net profit attributable to shareholders of 178.37 million yuan, up 64.64% year-on-year[67] - Gross profit margin for the main business was 52.81%, a slight decrease of 0.26 percentage points compared to the same period last year[69] - Revenue from preclinical research services increased by 56.23% to 628.84 million yuan, with a gross margin of 53.31%[70] - Sales expenses increased by 88.24% to 12.47 million yuan, primarily due to increased employee compensation and business volume[75] - R&D investment totaled 39.63 million yuan, accounting for 6.20% of total revenue, with 98 R&D personnel making up 8.31% of the company's total workforce[75] - Net cash flow from operating activities decreased by 15.89% to 148.09 million yuan, mainly due to delayed payments, increased employee compensation, and higher procurement costs[77] - Net cash flow from investing activities increased by 62.12% to -102.09 million yuan, driven by the recovery of short-term cash management principal[77] - The top five

2019 年第三季度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2019 年第三季度报告 1 / 28 2019 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 28 2019 年第三季度报告 单位：元 币种：人民币 3 / 28 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人冯宇霞、主管会计工作负责人高大鹏及会计机构负责人（会计主管人员）高大鹏 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-------------------------------------------------|------------------------------|------------------------- ...

2019 年半年度报告 公司代码：603127 公司简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2019 年半年度报告 1 / 164 2019 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人冯宇霞、主管会计工作负责人高大鹏及会计机构负责人（会计主管人员）高大鹏 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 半年度报告涉及未来计划、发展战略等前瞻性描述，因存在不确定性因素，不构成公司对投 资者的实质性承诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司在半年度报告中已描述相关经营风险，详情请查阅本报告第四节经营情况讨论与分析。 十、 其他 □适用 √不适用 ...